Latest News
Taiwan Bio signs pact with US-based TRACT Therapeutics

Source: BioSpectrum Asia

Taiwan Bio and US-based TRACT Therapeutics have announced new strategic partnership to advance a cellular therapy to revolutionise the prevention of allograft rejection in solid organ transplant.

The partners will launch a multi-center Phase 2 clinical trial investigating the reduction of immunosuppressant drugs in living donor kidney transplant recipients in both the United States (US) and Taiwan.

This partnership leverages Taiwan Bio’s world-class expertise in cellular therapy manufacturing and TRACT Therapeutics’ innovative immune modulating regulatory T cell therapy platform.

By combining their strengths, the companies are set to explore new frontiers in enabling allogeneic tissue transplant with a focus on enhanced patient outcomes and improved quality of life. The upcoming Phase 2 trial builds upon the promising results from a Phase 1 study which demonstrated an excellent safety profile and encouraging efficacy signals with TRACT’s autologous Treg product, TregCel.

The Phase 2 clinical trial represents the first collaborative effort between the two companies, and further updates on the trial's progress will be shared in the coming months.

Information appearing on this website (images and texts, unless otherwise indicated) is the property of IBMI. To use or share, please indicate the source.
© 2024 Institute for Biotechnology and Medicine Industry (IBMI) All rights reserved.
Address:16F.-1, No.3, Park St., Nangang Dist., Taipei City 115, Taiwan (R.O.C.) Contact Number:(02)2655-8168 Fax:(02)2655-7978